Cancer development is closely associated with immunosuppressive tumor
microenvironment (TME) that attenuates antitumor immune responses and promotes tumor …

The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …

CD8+ T cells are critical for elimination of cancer cells. Factors within the tumor
microenvironment (TME) can drive these cells to a hypofunctional state known as …

Regulatory T (Treg) cells, although vital for immune homeostasis, also represent a major
barrier to anti-cancer immunity, as the tumour microenvironment (TME) promotes the …

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …

Cellular metabolism regulates immune cell activation, differentiation and effector functions,
but current metabolic approaches lack single-cell resolution and simultaneous …

Treatment of cancer has been revolutionized by immune checkpoint blockade therapies.
Despite the high rate of response in advanced melanoma, the majority of patients succumb …

The ATP–adenosine pathway functions as a key modulator of innate and adaptive immunity
within the tumour microenvironment. Consequently, multiple clinical strategies are being …

Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving
to be effective at restoring T cell-mediated immune responses that can lead to marked and …

Identifying tumor antigen-specific T cells from cancer patients has important implications for
immunotherapy diagnostics and therapeutics. Here, we show that CD103+ CD39+ tumor …